Pharmacodynamics, Population Dynamics, and the Evolution of Persistence in

English version České info

When growing populations of bacteria are confronted with bactericidal antibiotics, the vast majority of cells are killed, but subpopulations of genetically susceptible but phenotypically resistant bacteria survive. In accord with the prevailing view, these “persisters” are non- or slowly dividing cells randomly generated from the dominant population. Antibiotics enrich populations for pre-existing persisters but play no role in their generation. The results of recent studies with Escherichia coli suggest that at least one antibiotic, ciprofloxacin, can contribute to the generation of persisters. To more generally elucidate the role of antibiotics in the generation of and selection for persisters and the nature of persistence in general, we use mathematical models and experiments with Staphylococcus aureus (Newman) and the antibiotics ciprofloxacin, gentamicin, vancomycin, and oxacillin. Our results indicate that the level of persistence varies among these drugs and their concentrations, and there is considerable variation in this level among independent cultures and mixtures of independent cultures. A model that assumes that the rate of production of persisters is low and persisters grow slowly in the presence of antibiotics can account for these observations. As predicted by this model, pre-treatment with sub-MIC concentrations of antibiotics substantially increases the level of persistence to drugs other than those with which the population is pre-treated. Collectively, the results of this jointly theoretical and experimental study along with other observations support the hypothesis that persistence is the product of many different kinds of errors in cell replication that result in transient periods of non-replication and/or slowed metabolism by individual cells in growing populations. This Persistence as Stuff Happens (PaSH) hypothesis can account for the ubiquity of this phenomenon. Like mutation, persistence is inevitable rather than an evolved character. What evolved and have been identified are genes and processes that affect the frequency of persisters.

Vyšlo v časopise: Pharmacodynamics, Population Dynamics, and the Evolution of Persistence in. PLoS Genet 9(1): e32767. doi:10.1371/journal.pgen.1003123
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1003123

Souhrn

Zdroje

1. Gonzalez-PastorJE, HobbsEC, LosickR (2003) Cannibalism by sporulating bacteria. Science 301: 510–513.

2. DubnauD, LosickR (2006) Bistability in bacteria. Mol Microbiol 61: 564–572.

3. ArkinA, RossJ, McAdamsHH (1998) Stochastic kinetic analysis of developmental pathway bifurcation in phage lambda-infected Escherichia coli cells. Genetics 149: 1633–1648.

4. KaernM, ElstonTC, BlakeWJ, CollinsJJ (2005) Stochasticity in gene expression: from theories to phenotypes. Nat Rev Genet 6: 451–464.

5. HillSA, DaviesJK (2009) Pilin gene variation in Neisseria gonorrhoeae: reassessing the old paradigms. FEMS Microbiol Rev 33: 521–530.

6. HakanssonS, BergholmAM, HolmSE, WagnerB, WagnerM (1988) Properties of high and low density subpopulations of group B streptococci: enhanced virulence of the low density variant. Microb Pathog 5: 345–355.

7. BiggerJW (1944) Treatment of Staphylococcal infections with penicillin. The Lancet 2: 497–500.

8. SorianoF, GreenwoodD (1979) Action and interaction of penicillin and gentamicin on enterococci. J Clin Pathol 32: 1174–1179.

9. MeyerK, ChaffeeE, HobbyGL, DawsonMH, SchwenkE, et al. (1942) On Penicillin. Science 96: 20–21.

10. McDermottW (1958) Microbial persistence. Yale J Biol Med 30: 257–291.

11. GreenwoodD, O'GradyF (1970) Trimodal response of Escherichia coli and Proteus mirabilis to penicillins. Nature 228: 457–458.

12. PattynSR, DockxP, RollierMT, RollierR, SaerensEJ (1976) Mycobacterium leprae persisters after treatment with dapsone and rifampicin. Int J Lepr Other Mycobact Dis 44: 154–158.

13. SinghR, BarryCE3rd, BoshoffHI (2010) The three RelE homologs of Mycobacterium tuberculosis have individual, drug-specific effects on bacterial antibiotic tolerance. J Bacteriol 192: 1279–1291.

14. ShapiroJA, NguyenVL, ChamberlainNR (2011) Evidence for persisters in Staphylococcus epidermidis RP62a planktonic cultures and biofilms. J Med Microbiol 60: 950–960.

15. SpoeringAL, LewisK (2001) Biofilms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials. J Bacteriol 183: 6746–6751.

16. ShahD, ZhangZ, KhodurskyA, KaldaluN, KurgK, et al. (2006) Persisters: a distinct physiological state of E. coli. BMC Microbiol 6: 53.

17. LaFleurMD, KumamotoCA, LewisK (2006) Candida albicans biofilms produce antifungal-tolerant persister cells. Antimicrob Agents Chemother 50: 3839–3846.

18. HarrisonJJ, TurnerRJ, CeriH (2007) A subpopulation of Candida albicans and Candida tropicalis biofilm cells are highly tolerant to chelating agents. FEMS Microbiol Lett 272: 172–181.

19. DawsonC, IntapaC, Jabra-RizkMA (2011) “Persisters”: survival at the cellular level. PLoS Pathog 7: e1002121 doi:10.1371/journal.ppat.1002121.

20. WiuffC, ZappalaRM, RegoesRR, GarnerKN, BaqueroF, et al. (2005) Phenotypic tolerance: antibiotic enrichment of noninherited resistance in bacterial populations. Antimicrob Agents Chemother 49: 1483–1494.

21. LevinBR, RozenDE (2006) Non-inherited antibiotic resistance. Nat Rev Microbiol 4: 556–562.

22. MulcahyLR, BurnsJL, LoryS, LewisK (2010) Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. J Bacteriol 192: 6191–6199.

23. LafleurMD, QiQ, LewisK (2010) Patients with long-term oral carriage harbor high-persister mutants of Candida albicans. Antimicrob Agents Chemother 54: 39–44.

24. BalabanNQ, MerrinJ, ChaitR, KowalikL, LeiblerS (2004) Bacterial persistence as a phenotypic switch. Science 305: 1622–1625.

25. KussellE, KishonyR, BalabanNQ, LeiblerS (2005) Bacterial persistence: a model of survival in changing environments. Genetics 169: 1807–1814.

26. KerenI, ShahD, SpoeringA, KaldaluN, LewisK (2004) Specialized persister cells and the mechanism of multidrug tolerance in Escherichia coli. Journal of Bacteriology 186: 8172–8180.

27. JoersA, KaldaluN, TensonT (2010) The frequency of persisters in Escherichia coli reflects the kinetics of awakening from dormancy. J Bacteriol 192: 3379–3384.

28. GefenO, GabayC, MumcuogluM, EngelG, BalabanNQ (2008) Single-cell protein induction dynamics reveals a period of vulnerability to antibiotics in persister bacteria. Proc Natl Acad Sci U S A 105: 6145–6149.

29. DorrT, LewisK, VulicM (2009) SOS response induces persistence to fluoroquinolones in Escherichia coli. PLoS Genet 5: e1000760 doi:10.1371/journal.pgen.1000760.

30. DorrT, VulicM, LewisK (2010) Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli. PLoS Biol 8: e1000317 doi:10.1371/journal.pbio.1000317.

31. RegoesRR, WiuffC, ZappalaRM, GarnerKN, BaqueroF, et al. (2004) Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens. Antimicrob Agents Chemother 48: 3670–3676.

32. DuthieES, LorenzLL (1952) Staphylococcal coagulase; mode of action and antigenicity. J Gen Microbiol 6: 95–107.

33. BertaniG (1951) Studies on lysogenesis. I. The mode of phage liberation by lysogenic Escherichia coli. J Bacteriol 62: 293–300.

34. BertaniG (2004) Lysogeny at mid-twentieth century: P1, P2, and other experimental systems. J Bacteriol 186: 595–600.

35. Institute CaLS (2009) Methods of Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Vol. 29 No. 2 ed. Wayne, Pennsylvania: Clinical and Laboratory Standards Institute.

36. LuriaSE, DelbruckM (1943) Mutations of Bacteria from Virus Sensitivity to Virus Resistance. Genetics 28: 491–511.

37. AllisonKR, BrynildsenMP, CollinsJJ (2011) Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature 473: 216–220.

38. VegaNM, AllisonKR, KhalilAS, CollinsJJ (2012) Signaling-mediated bacterial persister formation. Nat Chem Biol

39. FerulloDJ, LovettST (2008) The stringent response and cell cycle arrest in Escherichia coli. PLoS Genet 4: e1000300 doi:10.1371/journal.pgen.1000300.

40. GullbergE, CaoS, BergOG, IlbackC, SandegrenL, et al. (2011) Selection of resistant bacteria at very low antibiotic concentrations. PLoS Pathog 7: e1002158 doi:10.1371/journal.ppat.1002158.

41. FauvartM, De GrooteVN, MichielsJ (2011) Role of persister cells in chronic infections: clinical relevance and perspectives on anti-persister therapies. J Med Microbiol 60: 699–709.

42. AllisonKR, BrynildsenMP, CollinsJJ (2011) Heterogeneous bacterial persisters and engineering approaches to eliminate them. Curr Opin Microbiol 14: 593–598.

43. BalabanNQ (2011) Persistence: mechanisms for triggering and enhancing phenotypic variability. Current Opinion in Genetics & Development 21: 768–775.

44. LewisK (2010) Persister cells. Annu Rev Microbiol 64: 357–372.

45. LewisK (2005) Persister cells and the riddle of biofilm survival. Biochemistry (Mosc) 70: 267–274.

46. JayaramanR (2008) Bacterial persistence: some new insights into an old phenomenon. J Biosci 33: 795–805.

47. HansenS, LewisK, VulicM (2008) Role of global regulators and nucleotide metabolism in antibiotic tolerance in Escherichia coli. Antimicrob Agents Chemother 52: 2718–2726.

48. Vazquez-LaslopN, LeeH, NeyfakhAA (2006) Increased persistence in Escherichia coli caused by controlled expression of toxins or other unrelated proteins. J Bacteriol 188: 3494–3497.

49. MaisonneuveE, ShakespeareLJ, JorgensenMG, GerdesK (2011) Bacterial persistence by RNA endonucleases. Proc Natl Acad Sci U S A 108: 13206–13211.

50. LuidaleppH, JoersA, KaldaluN, TensonT (2011) Age of inoculum strongly influences persister frequency and can mask effects of mutations implicated in altered persistence. J Bacteriol 193: 3598–3605.

51. ChenX, ZhangM, ZhouC, KallenbachNR, RenD (2011) Control of bacterial persister cells by trp/arg-containing antimicrobial peptides. Appl Environ Microbiol 77: 4878–4885.

52. CorreiaFF, D'OnofrioA, RejtarT, LiL, KargerBL, et al. (2006) Kinase activity of overexpressed HipA is required for growth arrest and multidrug tolerance in Escherichia coli. J Bacteriol 188: 8360–8367.

53. SpoeringAL, VulicM, LewisK (2006) GlpD and PlsB participate in persister cell formation in Escherichia coli. J Bacteriol 188: 5136–5144.

54. MaartinF, GrooteVD, MichielsJ (2011) Role of persister cells in chronic infections: clinical relevance and perspectives on anti-persister therapies. J Med Microbiol June 2011 60: 699–709. J Med Microbiol 60.

55. JohnsenPJ, DubnauD, LevinBR (2009) Episodic selection and the maintenance of competence and natural transformation in Bacillus subtilis. Genetics 181: 1521–1533.

56. MoyedHS, BertrandKP (1983) hipA, a newly recognized gene of Escherichia coli K-12 that affects frequency of persistence after inhibition of murein synthesis. J Bacteriol 155: 768–775.

57. MoyedHS, BroderickSH (1986) Molecular cloning and expression of hipA, a gene of Escherichia coli K-12 that affects frequency of persistence after inhibition of murein synthesis. J Bacteriol 166: 399–403.

58. MonodJ (1949) The growth of bacterial cultures. Annual Review of Microbiology 3: 371–394.

59. StewartFM, LevinBR (1973) Resource partitioning and the outcome of interspecific competition: a model and some general considerations. American Naturalist 107 171–198.